$EYPT
EyePoint Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022022141 Filed on November 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $10.53M $10.01M $9.059M
YoY Change -8.76% 10.52% -42.3%
Cost Of Revenue $3.410M $1.405M $1.825M
YoY Change 12.43% -23.01% -2.93%
Gross Profit $7.123M $8.607M $7.234M
YoY Change -16.31% 18.98% -47.62%
Gross Profit Margin 67.63% 85.97% 79.85%
Selling, General & Admin $14.41M $15.23M $13.43M
YoY Change -15.37% 13.35% 21.36%
% of Gross Profit 202.32% 176.93% 185.71%
Research & Development $15.54M $11.16M $8.498M
YoY Change 74.29% 31.35% 107.78%
% of Gross Profit 218.21% 129.69% 117.47%
Depreciation & Amortization $335.0K $615.0K $701.0K
YoY Change -52.01% -12.27% 4.63%
% of Gross Profit 4.7% 7.15% 9.69%
Operating Expenses $30.16M $28.41M $22.55M
YoY Change 13.55% 26.0% 42.97%
Operating Profit -$23.04M -$18.40M -$15.31M
YoY Change 27.62% 20.15% 681.28%
Interest Expense $283.0K $662.0K -$1.382M
YoY Change -120.48% -147.9% -24.89%
% of Operating Profit
Other Income/Expense, Net -$22.00K -$1.382M
YoY Change -98.41%
Pretax Income -$43.45M -$18.42M -$16.70M
YoY Change 123.61% 10.33% 339.34%
Income Tax
% Of Pretax Income
Net Earnings -$43.45M -$18.42M -$16.70M
YoY Change 123.61% 10.33% 339.23%
Net Earnings / Revenue -412.53% -183.98% -184.29%
Basic Earnings Per Share -$0.49 -$0.58
Diluted Earnings Per Share -$1.16 -$0.49 -$580.4K
COMMON SHARES
Basic Shares Outstanding 34.08M 34.07M 28.77M
Diluted Shares Outstanding 37.34M 28.77M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $144.6M $157.3M $119.7M
YoY Change -31.68% 31.37% 317.11%
Cash & Equivalents $95.63M $75.36M $119.7M
Short-Term Investments $48.93M $81.90M
Other Short-Term Assets $782.0K $10.44M $3.892M
YoY Change -81.46% 168.14% -32.9%
Inventory $2.886M $3.531M $4.571M
Prepaid Expenses $2.723M
Receivables $15.50M $20.88M $13.60M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $172.8M $192.1M $141.8M
YoY Change -27.31% 35.5% 197.85%
LONG-TERM ASSETS
Property, Plant & Equipment $1.360M $1.015M $2.962M
YoY Change 185.71% -65.73% -7.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $150.0K $150.0K $150.0K
YoY Change 0.0% 0.0% -25.0%
Total Long-Term Assets $7.548M $28.39M $26.48M
YoY Change -70.55% 7.22% -9.33%
TOTAL ASSETS
Total Short-Term Assets $172.8M $192.1M $141.8M
Total Long-Term Assets $7.548M $28.39M $26.48M
Total Assets $180.4M $220.5M $168.3M
YoY Change -31.52% 31.05% 119.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.919M $6.112M $6.639M
YoY Change -19.85% -7.94% 27.67%
Accrued Expenses $16.36M $16.00M $11.46M
YoY Change 13.43% 39.61% 67.47%
Deferred Revenue
YoY Change
Short-Term Debt $10.48M $10.48M $0.00
YoY Change
Long-Term Debt Due $36.00K $70.00K $147.0K
YoY Change -73.72% -52.38% 47.0%
Total Short-Term Liabilities $34.54M $34.26M $19.93M
YoY Change 45.98% 71.86% 54.52%
LONG-TERM LIABILITIES
Long-Term Debt $29.31M $29.25M $36.47M
YoY Change -19.83% -19.79% -28.22%
Other Long-Term Liabilities $600.0K $600.0K $19.10M
YoY Change -74.49% -96.86% 247.35%
Total Long-Term Liabilities $29.91M $29.85M $55.57M
YoY Change -23.14% -46.28% -1.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.54M $34.26M $19.93M
Total Long-Term Liabilities $29.91M $29.85M $55.57M
Total Liabilities $83.99M $84.14M $75.50M
YoY Change 6.32% 11.44% 9.11%
SHAREHOLDERS EQUITY
Retained Earnings -$671.4M -$627.9M
YoY Change 17.97%
Common Stock $766.9M $763.6M
YoY Change 1.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $96.37M $136.4M $92.75M
YoY Change
Total Liabilities & Shareholders Equity $180.4M $220.5M $168.3M
YoY Change -31.52% 31.05% 119.08%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$43.45M -$18.42M -$16.70M
YoY Change 123.61% 10.33% 339.23%
Depreciation, Depletion And Amortization $335.0K $615.0K $701.0K
YoY Change -52.01% -12.27% 4.63%
Cash From Operating Activities -$12.59M -$13.14M -$7.787M
YoY Change -24.48% 68.69% -783.07%
INVESTING ACTIVITIES
Capital Expenditures $585.0K -$1.198M -$131.0K
YoY Change 814.5% 0.77%
Acquisitions
YoY Change
Other Investing Activities $33.50M $7.470M
YoY Change -201.63%
Cash From Investing Activities $32.92M $6.272M -$131.0K
YoY Change -199.85% -4887.79% 0.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -58.00K 92.00K -2.000K
YoY Change -100.05% -4700.0% -100.04%
NET CHANGE
Cash From Operating Activities -12.59M -13.14M -7.787M
Cash From Investing Activities 32.92M 6.272M -131.0K
Cash From Financing Activities -58.00K 92.00K -2.000K
Net Change In Cash 20.27M -6.772M -7.920M
YoY Change -65.57% -14.49% -234.01%
FREE CASH FLOW
Cash From Operating Activities -$12.59M -$13.14M -$7.787M
Capital Expenditures $585.0K -$1.198M -$131.0K
Free Cash Flow -$13.17M -$11.94M -$7.656M
YoY Change -20.97% 55.93% -702.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001314102
dei Document Type
DocumentType
10-Q
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51122
dei Entity Registrant Name
EntityRegistrantName
EyePoint Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2774444
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Pleasant Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
(617)
dei Local Phone Number
LocalPhoneNumber
926-5000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
EYPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34082934
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75362000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178593000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
81897000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
32965000
CY2022Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
20876000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
18354000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10436000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4217000
CY2022Q3 us-gaap Inventory Net
InventoryNet
3531000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3616000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
192102000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
237745000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1015000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
476000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6319000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2252000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20904000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22749000
CY2022Q3 us-gaap Assets
Assets
220490000
CY2021Q4 us-gaap Assets
Assets
263372000
CY2022Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
10475000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6112000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7385000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16004000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14422000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1169000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1069000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
496000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
782000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
34256000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23658000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29251000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
36562000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
13798000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14560000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6235000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1860000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
600000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2352000
CY2022Q3 us-gaap Liabilities
Liabilities
84140000
CY2021Q4 us-gaap Liabilities
Liabilities
78992000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34072155
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34072155
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33905826
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33905826
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
34000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
763562000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
752602000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-627899000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-569097000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
653000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
841000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30871000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25395000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2065000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
136350000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184380000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220490000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263372000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10012000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9059000
CY2022Q3 eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
1405000
CY2021Q3 eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
1825000
eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
4916000
eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
5144000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11162000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8498000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34099000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19582000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6016000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7374000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19592000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19692000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9212000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6060000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26321000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16358000
CY2022Q3 eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
615000
CY2021Q3 eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
615000
eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
1845000
eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
1845000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
28410000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
24372000
us-gaap Operating Expenses
OperatingExpenses
86773000
us-gaap Operating Expenses
OperatingExpenses
62621000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18398000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15313000
us-gaap Operating Income Loss
OperatingIncomeLoss
-55902000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37226000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
640000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1067000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
286000
CY2022Q3 us-gaap Interest Expense
InterestExpense
662000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1388000
us-gaap Interest Expense
InterestExpense
2408000
us-gaap Interest Expense
InterestExpense
4110000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1559000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1382000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2900000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1759000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18420000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16695000
us-gaap Net Income Loss
NetIncomeLoss
-58802000
us-gaap Net Income Loss
NetIncomeLoss
-38985000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37338000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37338000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28766000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28766000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37305000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37305000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27429000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27429000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18420000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16695000
us-gaap Net Income Loss
NetIncomeLoss
-58802000
us-gaap Net Income Loss
NetIncomeLoss
-38985000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
51000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-188000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18369000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16695000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58990000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38985000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
106865000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16695000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
101000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-5000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2471000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
92748000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
151366000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18420000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
51000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
153000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
156000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-145000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50182000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3199000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
136350000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
18541000
us-gaap Net Income Loss
NetIncomeLoss
-38985000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108414000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
273000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4639000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
92748000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184380000
us-gaap Net Income Loss
NetIncomeLoss
-58802000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-188000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
354000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-271000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10816000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
136350000
us-gaap Profit Loss
ProfitLoss
-58802000
us-gaap Profit Loss
ProfitLoss
-38985000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1845000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1845000
us-gaap Depreciation
Depreciation
266000
us-gaap Depreciation
Depreciation
228000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
-218000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
462000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1559000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2065000
us-gaap Share Based Compensation
ShareBasedCompensation
10816000
us-gaap Share Based Compensation
ShareBasedCompensation
4639000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
8942000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
4622000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-85000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-767000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1681000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5030000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
-44000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
6000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-663000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-734000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52417000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33429000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
125617000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
77000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1565000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2294000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108349000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
30000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
32409000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
599000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
38235000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
271000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
21934000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Operating Lease Expense
OperatingLeaseExpense
656000
us-gaap Variable Lease Cost
VariableLeaseCost
8000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
145000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
395000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
284000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
103000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
102000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-632000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108386000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-103231000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
74801000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178743000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45059000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75512000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119860000
us-gaap Interest Paid Net
InterestPaidNet
1907000
us-gaap Interest Paid Net
InterestPaidNet
3624000
eypt Debt Instrument Exit Fee
DebtInstrumentExitFee
600000
eypt Debt Instrument Exit Fee
DebtInstrumentExitFee
0
eypt Payments Forgiven Under Paycheck Protection Program Loan
PaymentsForgivenUnderPaycheckProtectionProgramLoan
0
eypt Payments Forgiven Under Paycheck Protection Program Loan
PaymentsForgivenUnderPaycheckProtectionProgramLoan
2041000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;font-size:0;margin-top:10.0pt;line-height:1.0925;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operations</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), as of September 30, 2022 and for the three and nine months ended September 30, 2022 and 2021 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (“U.S.”) generally accepted accounting principles requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery anti-VEGF treatment currently in Phase 2 clinical trials for wet age-related macular degeneration (“wet AMD”), the leading cause of vision loss among people 50 years of age and older in the United States and non-proliferative diabetic retinopathy. The Company also has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> commercial products: YUTIQ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a once every three-year treatment for posterior segment uveitis of the eye, and DEXYCU</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a single-dose treatment for postoperative inflammation following ocular surgery. Both commercial products are currently being sold in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to identify and advance additional pipeline product candidates through clinical and regulatory development. This may be accomplished through internal discovery efforts, research collaborations and/or in-licensing arrangements with partner molecules and potential acquisitions of additional ophthalmic products, product candidates or technologies that complement the Company’s current product portfolio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effects of the COVID-19 Coronavirus Pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ongoing COVID-19 coronavirus pandemic (the “Pandemic”) has had a material and adverse impact on the Company’s business. The duration and full extent to which the Pandemic impacts the Company’s business, revenues, financial condition and cash flows depend on future developments that are highly uncertain, subject to change and are difficult to predict, including new information that may emerge concerning the Pandemic, and may cause intermittent or prolonged periods of reduced patient services at the Company’s customers’ facilities, which may negatively affect customer demand. The Company’s revenues, financial condition and cash flows may be adversely affected in the future as well. The Company is continuously monitoring the Pandemic and its potential effect on the Company’s financial position, results of operations and cash flows. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company’s periodic financial results, including reserves for variable consideration related to product sales, realizability of certain receivables, assessment for excess or obsolete inventory and impairment of long-lived assets. Uncertainty around the extent and length of time of the Pandemic, and any future related financial impact cannot be reasonably estimated at this time.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company had cash, cash equivalents and investments in marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at September 30, 2022. The Company has a history of operating losses and has not had significant recurring cash inflows from revenue. The Company’s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from its collaboration partners. The Company anticipates that it will continue to incur losses as it continues the research and development of its product candidates, and the Company does not expect revenues from its product sales to generate sufficient funding to sustain its operations in the near-term. The Company expects to continue fulfilling its funding needs through cash inflows from revenues of its product sales, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash, cash equivalents and investments in marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at September 30, 2022 coupled with expected net cash inflows from its product sales will enable the Company to fund its current and planned operations for at least the next twelve months from the date these consolidated financial statements were issued. Actual cash requirements could differ from management’s projections due to many factors, including the continued effect of the Pandemic on the Company’s business and the medical community, the timing and results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company’s clinical trials for EYP-1901, additional investments in research and development programs, the success of ongoing commercialization efforts for YUTIQ and DEXYCU, the actual costs of these ongoing commercialization efforts, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Adopted and Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. The Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.</span></p>
eypt Number Of Products
NumberOfProducts
2
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
157300000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
157300000
CY2021Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3353000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
14801000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-13644000
CY2022Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
4510000
CY2020Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1712000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
9382000
eypt Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
-272000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-7739000
CY2021Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3083000
us-gaap Variable Lease Cost
VariableLeaseCost
27000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
164000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
236000
us-gaap Operating Lease Payments
OperatingLeasePayments
595000
CY2021Q4 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
2974000
us-gaap Operating Lease Payments
OperatingLeasePayments
678000
CY2022Q3 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
1358000
CY2021Q4 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
1518000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1077000
CY2022Q3 eypt Finance Lease Property And Equipment Gross
FinanceLeasePropertyAndEquipmentGross
270000
CY2021Q4 eypt Finance Lease Property And Equipment Gross
FinanceLeasePropertyAndEquipmentGross
371000
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1696000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2727000
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
854000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
405000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
981000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
484000
CY2022Q3 us-gaap Inventory Net
InventoryNet
3531000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3616000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
45573000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
43113000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1845000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1845000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
47418000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44958000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20904000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23364000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P13Y
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1144000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16004000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14422000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
263000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
229000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2900000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2900000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
2000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
9000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6547000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7321000
CY2022Q3 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
2084000
CY2021Q4 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
753000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1011000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
712000
CY2022Q3 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
3927000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0589
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
425000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
645000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6235000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1860000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6660000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2505000
us-gaap Operating Lease Expense
OperatingLeaseExpense
781000
CY2022Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
2000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
64000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
166000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7953000
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
72000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1293000
CY2022Q3 eypt Finance Lease Accumulated Amortization Property And Equipment
FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
206000
CY2021Q4 eypt Finance Lease Accumulated Amortization Property And Equipment
FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
205000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
70000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
137000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
36000
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
70000
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
173000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
34000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
101000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
11000
CY2022Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
11000
CY2022Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
35000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
103000
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
46000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
108000
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
17000
CY2021Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
7000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
17000
CY2021Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
45000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
102000
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.125
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
239000
CY2022Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
35000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
910000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
37000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1392000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1494000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1589000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2022Q3 eypt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2329000
CY2022Q3 eypt Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
0
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6660000
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
70000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
9167000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10000000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10000000
CY2022Q3 eypt Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
833000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
30000000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3199000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2471000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10816000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4639000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M24D
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
81900000
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
155600000
CY2021Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
16500000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
33000000.0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4622875
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2460180

Files In Submission

Name View Source Status
0000950170-22-022141-index-headers.html Edgar Link pending
0000950170-22-022141-index.html Edgar Link pending
0000950170-22-022141.txt Edgar Link pending
0000950170-22-022141-xbrl.zip Edgar Link pending
eypt-20220930.htm Edgar Link pending
eypt-20220930.xsd Edgar Link pending
eypt-ex31_1.htm Edgar Link pending
eypt-ex31_2.htm Edgar Link pending
eypt-ex32_1.htm Edgar Link pending
eypt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
eypt-20220930_def.xml Edgar Link unprocessable
eypt-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eypt-20220930_pre.xml Edgar Link unprocessable
eypt-20220930_htm.xml Edgar Link completed
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eypt-20220930_cal.xml Edgar Link unprocessable